Share on StockTwits

Dr. Reddy’s Laboratories Limited (NYSE:RDY) announced its earnings results on Tuesday. The company reported $0.47 earnings per share for the quarter, ARN reports. The company had revenue of $580.00 million for the quarter, compared to the consensus estimate of $557.00 million.

A number of research firms have recently commented on RDY. Analysts at Zacks reiterated an “outperform” rating on shares of Dr. Reddy’s Laboratories Limited in a research note on Friday. They now have a $54.00 price target on the stock. On a related note, analysts at TheStreet upgraded shares of Dr. Reddy’s Laboratories Limited from a “hold” rating to a “buy” rating in a research note on Friday, March 28th.

Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) opened at 46.08 on Tuesday. Dr. Reddy’s Laboratories Limited has a 52-week low of $31.32 and a 52-week high of $47.93. The stock has a 50-day moving average of $43.9 and a 200-day moving average of $42.30. The company has a market cap of $7.838 billion and a P/E ratio of 20.79.

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is an integrated pharmaceutical company focused on providing medicines through its three business segments: Global Generics segment, Pharmaceutical Services and Active Ingredients (PSAI) segment and Proprietary Products segment.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.